ZURICH (Reuters) -Novartis will expand its operations in North Carolina and build a manufacturing hub there as part of a planned $23 billion of U.S. infrastructure investment over the next five years, the Swiss pharmaceuticals company said on Wednesday.
The expansion is projected to create 700 new positions at Novartis and more than 3,000 indirect jobs across the supply chain by 2030, the company's statement said.
The announcement follows a preliminary deal struck by the U.S. and Swiss governments last week to cut U.S. tariffs on Switzerland to 15% from 39%.
Central to the deal is a pledge by Swiss companies such as Novartis to invest $200 billion in the U.S. by the end of 2028.
Novartis said the new hub, expected to open in 2027 or 2028, will comprise two new facilities in Durham, North Carolina, for biologics manufacturing and sterile packaging, and a site in Morrisville for solid dosage production and packaging.
Novartis said it will also expand its existing Durham campus to support sterile filling of biologics.
The expansion is designed to increase the company's manufacturing capacity so that all of its key U.S. medicines can be produced domestically, it said.
(Writing by Dave GrahamEditing by David Goodman)
The many ways that baking is winter therapy. With a delicious ending- Figure out How to Remain Persuaded During Your Internet based Degree Program
- 'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- Step by step instructions to Integrate Lab Precious stones into Special Adornments Pieces
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- New studies of old dogs help scientists understand where they came from
- April's full moon decides the date of Easter — here's how it works
- Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
